AstraZeneca Set to Buy More Chinese Drugs (China)
This article was originally published in PharmAsia News
Executive Summary
AstraZeneca has announced it will join the ranks of drug manufacturers choosing to obtain raw materials and active pharmaceutical ingredients from emerging Asian markets. Over the next three years, the company's Chinese contracts will grow from $10 million to $100 million. AstraZeneca has also announced intentions to enact a similar investment plan in India's drug manufacturing industry. The company's move is part of a larger goal to reduce drug production costs, in an effort to keep business lucrative. The industry's renewed respect for the bottom line comes as the result of fierce generic competition and dwindling global patent protection for brand-name drugs. Still, many companies are daunted by a lack of production safety standards and intellectual property rights in some countries. But the promise of improvements in regulatory conditions are making outsourcing to countries like China and India a hard deal for manufacturers to resist. (Click here for more - May Require Paid Subscription
You may also be interested in...
US Q1 Consumer Health Earnings Preview: Label This One Historic And Challenging But Promising
US OTC drug and supplement firms’ reports of results for the first three months of 2024 began on April 19 with P&G. JP Morgan analysts say while “some retailers in the US in particular” are reducing consumer health inventories, for the overall sector they expect “a healthier balance of positive volume and lower pricing contribution.”
Keeping Track: Cancer Approvals From Lumisight Imaging To Adjuvant Alecensa
The US FDA’s approval of Lumicell’s optical imaging agent Lumisight makes a dozen novel approvals in 2024 for the Center for Drug Evaluation and Research.
Partisan Politics Returns To US FDA Congressional Oversight
The US FDA has stood out as an agency that tends to draw broad bipartisan support amid a generally rancorous and divided Congress. A House hearing, however, may be a sign that those days are over.